Wei Zhuodu, Jeong Hyeon-Cheol, Kang Ye-Ji, Jang Jaesang, Kim Myoung-Hwan, Shin Kwang-Hee
College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 41566, Korea.
Korea United Pharm. Inc., Seoul 06116, Korea.
Transl Clin Pharmacol. 2022 Jun;30(2):99-111. doi: 10.12793/tcp.2022.30.e10. Epub 2022 Jun 15.
Duloxetine and thioctic acid (TA) are standard drugs for treating diabetic neuropathy, a primary complication associated with diabetes. In this study, ultra performance liquid chromatography coupled with tandem mass spectrometry methods was successfully developed and validated for quantifying duloxetine and TA in biological samples. The protein precipitation method was used to extract duloxetine, TA and their internal standards from beagle dog plasma. A Hypersil Gold C18 column (150 × 2.1 mm, 1.9 μm) was used for the experiment. Isocratic elution with 0.1% formic acid in acetonitrile (A) and 0.1% formic acid (B) was used for duloxetine, whereas a gradient elution with 0.03% acetic acid (A) and acetonitrile (B) was used for TA. The validated parameters included linearity, sensitivity, accuracy, precision, selectivity, matrix effect, stability, and recovery under different conditions. The linear ranges of the calibration curves for duloxetine and TA were 5-800 ng/mL and 5-1,000 ng/mL, respectively. An intra- and inter-run precision of ± 15% can be observed in all quality control samples. These methods were successfully used for pharmacokinetics (PKs) studies in beagle dogs to compare PK differences in a fixed-dose combination including duloxetine and TA and co-administration of the 2 drugs.
度洛西汀和硫辛酸(TA)是治疗糖尿病神经病变的标准药物,糖尿病神经病变是糖尿病的一种主要并发症。在本研究中,成功开发并验证了超高效液相色谱-串联质谱法用于定量生物样品中的度洛西汀和TA。采用蛋白沉淀法从比格犬血浆中提取度洛西汀、TA及其内标。实验使用Hypersil Gold C18柱(150×2.1 mm,1.9μm)。度洛西汀采用0.1%甲酸乙腈溶液(A)和0.1%甲酸(B)等度洗脱,而TA采用0.03%乙酸(A)和乙腈(B)梯度洗脱。验证的参数包括线性、灵敏度、准确度、精密度、选择性、基质效应、稳定性以及不同条件下的回收率。度洛西汀和TA校准曲线的线性范围分别为5-800 ng/mL和5-1000 ng/mL。在所有质量控制样品中,批内和批间精密度均在±15%以内。这些方法成功用于比格犬的药代动力学(PK)研究,以比较固定剂量组合(包括度洛西汀和TA)以及两种药物联合给药时的PK差异。